This drug is in the form of a pill and the company also has filed with the FDA for an injectable drug. The Genzyme division of Sanofi produced the drug, which Sanofi purchased for $20 billion about a year ago. There’s no cure for MS and it attacks the body’s nervous system. The drug should be on the market within a few weeks and is said to have milder side effects compared to other drugs on the market. BD
(Reuters) - French drugmaker Sanofi SA gained U.S. approval for its multiple sclerosis pill, Aubagio, on Wednesday -- one of the two MS treatments it is relying on to return to growth after several blockbuster drugs lost patent protection.
The drug has milder side effects than rival MS drugs and analysts say it could find favor among newly diagnosed patients.
Around 35 percent to 40 percent of MS patients prefer to take no medication rather than face unwanted side effects.
"In a clinical trial, the relapse rate for patients using Aubagio was about 30 percent lower than the rate for those taking a placebo," Russell Katz, director of the Division of Neurology Products at the Food and Drug Administration, said in a statement.
Aubagio is set to be on the U.S. market in a few weeks, a spokeswoman for Sanofi unit Genzyme said.